Biotechnology - Biotechnology, Genentech


Current filters:


Popular Filters

1 to 25 of 45 results

Xenon and Genentech establish new pain discovery collaboration


Privately-held US biotech firm Xenon Pharmaceuticals has established a new collaboration with Swiss drug…

BiotechnologyGenentechLicensingNeurologicalResearchRocheXenon Pharmaceuticals

US FDA clears Xolair for chronic idiopathic urticaria


Swiss drug major Novartis says the US Food and Drug Administration has approved Xolair (omalizumab) for…

BiotechnologyDermatologicalsGenentechNorth AmericaNovartisRegulationRocheUSAXolair

Roche advised to stop Ph III onartuzumab METLung study on lack of efficacy

Roche advised to stop Ph III onartuzumab METLung study on lack of efficacy


An independent data monitoring committee has recommended that Swiss drug major Roche’s Phase III METLung…


Genentech regains its dominance in image among oncologists

Genentech regains its dominance in image among oncologists


Genentech, the biotechnology subsidiary of Swiss drug major Roche, has made notable gains as the top…

AmgenBiotechnologyCelgeneGenentechHematologyMarkets & MarketingNovartisOncologyResearch

PDL BioPharma settles litigation with Genentech and Roche


US drugmaker PDL BioPharma has entered into an agreement with Genentech and its parent, Swiss drug major…

BiotechnologyFinancialGenentechLegalOncologyOphthalmicsPDL BioPharmaRoche

Roche’s Gazyva gains FDA approval of CLL

Roche’s Gazyva gains FDA approval of CLL


The US Food and Drug Administration late Friday approved Roche’s Gazyva (obinutuzumab), also known…

Biogen IdecBiotechnologyGazyvaGenentechMabTheraNorth AmericaobinutuzumabOncologyRegulationRituxanRoche

Roche investing 800 million Swiss francs to expand biologics production

Roche investing 800 million Swiss francs to expand biologics production


Roche said this morning it plans to invest 800 million Swiss francs ($879.2 million) within its global…

BiotechnologyEuropeFinancialGenentechKadcylaNorth AmericaPerjetaProductionRoActemraRoche

FDA advisory panel backs new indication for Genentech's Perjeta


The US Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) yesterday (September…

BiotechnologyGenentechKadcylaNorth AmericaOncologyPerjetaPharmaceuticalRegulationRoche

US Court denies re-hearing of Arzerra patent case


Danish drugmaker Genmab (OMX: GEN) says that the US Court of Appeals for the Federal Circuit has declined…

ArzerraBiogen IdecBiotechnologyGenentechGenmabGlaxoSmithKlineLegalNorth AmericaOncologyPatentsPharmaceutical

Conditional EU approval for Roche basal cell carcinoma drug


The European Commission has granted conditional approval to Swiss drug major Roche's (ROG: SIX) Erivedge…


Immunocore and Genentech collaborate to develop ImmTACs for multiple cancer targets


Immunocore, an Oxford, UK-based biotechnology company developing novel biological drugs known as ImmTACs…


PDL files for arbitration for alleged royalties underpayments by Genentech


USA-based PDL BioPharma (Nasdaq: PDLI) revealed today (June 11) that it has filed a Notice of Arbitration…

BiotechnologyFinancialGenentechLegalPDL BioPharmaPharmaceuticalRoche

Roche's Avastin extends lives of cervical cancer patients; positive in glioblastoma


Data presented from the study, known as GOG240, showed that the addition of Swiss pharma major Roche's…


Avastin remains preferred DME therapy, despite Lucentis extended label in USA


Despite the approval of Swiss drug major Roche (ROG: SIX) subsidiary Genentech's Lucentis (ranibizumab…

AvastinBayerBiotechnologyEyleaGenentechLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneronRoche

Strong initial data on Genentech's obinutuzumab in most common blood cancer


Genentech, the biotech subsidiary of Swiss drug major Roche Group (ROG: SIX), has announced positive…


US pulmonologists view refractory asthma patient treatment with biosimilar Xolair by end-2018


US pulmonologists surveyed by health care advisory firm Decision Resources estimate that only 19% percent…

BiotechnologyBoehringer IngelheimGenentechGenericsMarkets & MarketingNorth AmericaNovartisPfizerRespiratory and PulmonarySpirivaXolair

Genentech Ph III study of omalizumab shows promise in CIU


Genentech, the US biotech subsidiary of Swiss drug major Roche (ROG: SIX), announced results from a Phase…

BiotechnologyDermatologicalsGenentechNovartisOmalizumabPharmaceuticalRegulationResearchRespiratory and PulmonaryRocheXolair

US FDA approves Roche's late-stage breast cancer drug Kadcyla


The US Food and Drug Administration on Friday approved Kadcyla (ado-trastuzumab emtansine), a new therapy…

BiotechnologyGenentechImmunoGenKadcylaNorth AmericaOncologyPharmaceuticalRegulationRochetrastuzumab emtansine

Italy's antitrust body investigating Roche and Novartis for alleged cartel


The Italian antitrust authority has opened a cartel investigation of Swiss drug majors Novartis (NOVN:…


Genentech enters $111 million drug discovery pact with RQx Pharma


California, USA-based privately-held RQx Pharmaceuticals said yesterday that it has entered into a drug…

BiotechnologyGenentechLicensingRocheRQx Pharmaceuticals

US biotech giants lobbying to block biosimilars, NTY claims


Some of the USA's biggest biotechnology companies are lobbying intensively to limit generic competition…

AmgenBiotechnologyGenentechGenericsNorth AmericaPoliticsRegulation

FDA clears new use for Roche's Avastin and Novartis' Exjade


The US Food and Drug Administration has approved a new use for Swiss drug major Roche's (ROG: SIX) US…

AvastinBiotechnologyExjadeGenentechNorth AmericaNovartisOncologyPharmaceuticalRegulationRoche

San Antonio breast cancer meeting highlights


There was mixed news coming out of the San Antonio Breast Cancer Symposium (SABCS), which concluded on…


Curis in-licenses cancer candidate from Genentech


US drug development firm Curis (Nasdaq: CRIS) that it has licensed from Genentech, a subsidiary of Swiss…


1 to 25 of 45 results

Back to top